Johnson & Johnson and Johnson & Johnson Innovation‑JJDC, Inc. amend a Schedule 13G/A to report beneficial ownership of 152,901 shares of Rallybio Corporation common stock, representing 2.9% of the class. Percentage ownership is calculated using 5,289,675 shares outstanding as of March 6, 2026. The filing states the securities are directly owned by JJDC and that J&J may be deemed to indirectly beneficially own them; the amendment is signed April 13, 2026.
Positive
None.
Negative
None.
Insights
J&J reports a sub‑5% passive stake in Rallybio via its corporate VC arm.
Johnson & Johnson and its wholly owned subsidiary, Johnson & Johnson Innovation‑JJDC, report beneficial ownership of 152,901 shares (2.9%) of Rallybio common stock, calculated on a 5,289,675 share base as of March 6, 2026. The filing clarifies that JJDC directly holds the securities and J&J may be deemed an indirect beneficial owner.
The disclosure is a routine passive ownership update under Schedule 13G/A and carries no operational or financing commitments in the text; subsequent filings would be required to show any change in intent or additional transactions.
Key Figures
Reported shares beneficially owned:152,901 sharesPercent of class:2.9%Shares outstanding used for calculation:5,289,675 shares+2 more
5 metrics
Reported shares beneficially owned152,901 sharesDirectly beneficially owned by JJDC; reported in Schedule 13G/A
Percent of class2.9%Based on 5,289,675 shares outstanding as of March 6, 2026
Shares outstanding used for calculation5,289,675 sharesShares outstanding as of March 6, 2026 per Issuer's Form 10‑K
Signature date04/13/2026Amendment signed by reporting persons
Filing header date03/31/2026Date referenced at top of the amendment excerpt
Key Terms
Schedule 13G/A, beneficially owned, shared dispositive power
3 terms
Schedule 13G/Aregulatory
"This Amendment No. 1 to is filed by Johnson & Johnson"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownedfinancial
"The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerregulatory
"Shared Dispositive Power 152,901.00"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Rallybio Corporation
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
75120L209
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
75120L209
1
Names of Reporting Persons
Johnson & Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NEW JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
152,901.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
152,901.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
152,901.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
75120L209
1
Names of Reporting Persons
Johnson & Johnson Innovation - JJDC, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
152,901.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
152,901.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
152,901.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Rallybio Corporation
(b)
Address of issuer's principal executive offices:
234 Church Street, Suite 1020, New Haven, CT 06510
Item 2.
(a)
Name of person filing:
This Amendment No. 1 to Schedule 13G is filed by Johnson & Johnson, a New Jersey corporation ("J&J") and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation ("JJDC"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC and J&J may be deemed to indirectly beneficially own such securities. Reference is hereby made to the Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on July 30, 2024 (the "Schedule 13G"). The agreement between the Reporting Persons to file jointly (the "Joint Filing Agreement") was filed as Exhibit A to the Schedule 13G.
(b)
Address or principal business office or, if none, residence:
J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933
JJDC: 410 George Street, New Brunswick, NJ 08901
(c)
Citizenship:
J&J: NJ
JJDC: DE
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A.
(b)
Percent of class:
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A. Percentage ownership is based on 5,289,675 shares of Common Stock outstanding as of March 6, 2026, as reported in the Issuer's Report on Form 10-K for the period ended December 31, 2025 filed with the Securities and Exchange Commission on March 16, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A.
(ii) Shared power to vote or to direct the vote:
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A.
(iii) Sole power to dispose or to direct the disposition of:
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A.
(iv) Shared power to dispose or to direct the disposition of:
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G/A.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Johnson & Johnson hold in Rallybio (RLYB)?
Johnson & Johnson and JJDC report beneficial ownership of 152,901 shares, equal to 2.9% of Rallybio's common stock based on 5,289,675 shares outstanding as of March 6, 2026.
Who directly holds the Rallybio shares reported in the 13G/A?
The filing states the securities are directly beneficially owned by Johnson & Johnson Innovation‑JJDC, Inc. and that Johnson & Johnson may be deemed to indirectly beneficially own them.
When was the ownership percentage calculated for Rallybio?
Percentage ownership is based on 5,289,675 shares outstanding as of March 6, 2026, as reported in Rallybio's Form 10‑K for the period ended December 31, 2025.
Does the Schedule 13G/A indicate an intent to acquire control of Rallybio?
No intent to acquire control is stated; the amendment reports passive beneficial ownership by JJDC and an indirect attribution to J&J, consistent with a Schedule 13G/A passive disclosure.
When was this Schedule 13G/A amendment signed?
The amendment shows signatures dated April 13, 2026, and the cover header references March 31, 2026 as a filing date element in the excerpt.
